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ABSTRACT: ToF-SIMS is a label free imaging method that has been shown to enable imaging of amiodarone in single rat 
macrophage (NR8383) cells. In this study, we show the method extends to three other cell lines relevant to drug discovery:   Human 
embryonic kidney (HEK293), cervical cancer (HeLa) and liver cancer (HepG2). There is significant interest in the variation of drug 
uptake at the single cell level and we use ToF-SIMS to show that there is great diversity between individual cells and when comparing 
each of the cell types. These single cell measurements are compared to quantitative measurements of cell-associated amiodarone for 
the population using LC-MS/MS and cell counting with flow cytometry. NR8383 and HepG2 cells uptake the greatest amount of 
amiodarone with on average 2.38 and 2.60pg per cell respectively, and HeLa and Hek 293 have a significantly lower amount of 
amiodarone at 0.43 and 0.36 pg per cell respectively. The amount of cell-associated drug for the ensemble population measurement 
(LC-MS/MS) is compared with the ToF-SIMS single cell data: similar amount of drug was detected per cell for the NR8383, and 
HepG2 cells at a greater level that for the HEK293 cells. However, the two techniques did not agree for the HeLa cells and we 
postulate potential reasons for this. 
 
Since the beginning of the last century the pharmaceutical 
industry has transformed people’s lives, creating medicines that 
either cure diseases or in the worst-case scenario transform 
diseases that were regarded as terminal into chronic conditions. 
However, the development of new drugs is becoming 
increasingly challenging as a result of several factors including: 
increased target complexity, changing market demands, 
diminishing returns and ever-stricter safety requirements1. A 
paradigm shift in the drug discovery workflow is required to 
reduce new candidate attrition and transform classic drug 
screening assays into analytical platforms that allow better 
understanding of the compound’s behavior, effect and 
distribution in-vitro, ex-vivo and ideally in-vivo for both animal 
models and human patients. 
Drug discovery faces a struggle with reliable animal models that 
are effectively representative of the drug’s influence on the 
patient, hence its absolute reliance on clinical trials. Human 
clinical trials are always going to be a fundamental part of the 
drug development process, as only the human body can convey 
its complexity2,3. 
 There are several steps that precede human clinical trials that 
steer the direction of the drug discovery and development 
process. Generally, the drug discovery process within a disease 
area starts with identifying a potential target, by conducting 
experiments centered on the biology of the disease target, an 
endogenous entity responsible for the disease state in question 
(target identification). Typically, this is followed by a High 
Throughput Screening (HTS) campaign to identify molecules 
that have an effect on the target of interest (the discovery 
phase). This needs to be done in a time effective manner as 
pharmaceutical compound libraries are extensive 4,5. It is 
extremely challenging to design a screening campaign that has 
the necessary speed to cover sufficient candidate compounds in 
a biological system that is fully representative of the disease 
model studied. Hence, there is need to develop low throughput 
assays that follow these high throughput efforts to interrogate 
the mechanism behind the drug’s effect observed in the HTS 
and validate the compound activity in-vivo (lead validation)6–8. 
These assays are often cell and animal based. However, both 
the cell and the animal are like black boxes in that there is 
typically no detailed knowledge of the intricate complexity of 
the target’s biology and decisions are made based on phenotypic 
responses.9,10  
Too often the results of these efforts are negative and the project 
fails to find a suitable drug candidate. This can be for a number 
of reasons such as poor cell membrane permeability of the 
compounds, off target activity and inaccessibility of the target6. 
A better understanding of the reasons why the compound failed 
needs to be established, which requires the ability to see into the 
black box so the compound can be re-designed7. 
There are several techniques that are used currently to probe the 
biology of the disease target within a single cell11, all with 
strong points and limitations. For instance, MALDI (Matrix 
Assisted Laser Desorption Ionisation) has shown great results 
in characterizing the distribution of drug compounds in 
tissues12. However, it has traditionally had poor spatial 
resolution and, limiting its suitability for interrogating cells in 
culture, as it cannot resolve the sub-cellular distribution. Recent 
advances have improved the spatial resolution to below 5 µm 
allowing individual cells to be resolved, but sub-cellular 
structure are yet to be published13,14. Other disadvantages of 
MALDI are the requirement for a matrix and the fact that it does 
not produce three dimensional information, as the matrix 
extracts the analyte to the surface of the sample practically 
limiting 3D imaging to reconstruction from the analysis of 
sequential tissue sections.  
In contrast, electron and super-resolution light microscopy can 
resolve sub-cellular features. Recently, Chéreau, et al use STED 
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(stimulated emission depletion) microscopy to study 
morphological interactions between astrocytes and synapses 
with an approximate resolution of 20 nm per pixel15. This was 
achieved with the use of fluorescent tags and similarly a 
pharmaceutical compound could be labeled in order to 
determine its intracellular localization. However, this process 
will affect the physical-chemical properties of the 
pharmaceutical as fluorescent tags tend to be similar in 
molecular weight to the vast majority of small molecule 
pharmaceutical compounds16–19. LC-MS/MS can also be used 
to determine the presence of drug inside the cell20 as it is very 
sensitive and can be quantitative; however it provides no 
localization information since the cells must be lysed to extract 
the analyte. In summary, current technology is limited to either 
label-free at micron resolution or sub-micron resolution with 
the addition of tags. ToF-SIMS can bridge the gap as it allows 
compound identification based on molecular  mass and has 
good spatial resolution. Previously21, we demonstrated this in a 
macrophage cell line (NR8383) where amiodarone was 
identified and localized in 3D with a resolution of 3.4 µm for 
the intact drug molecule and 500 nm when using the more 
intense iodine signal (a characteristic element in the drug).  
This cellular model was chosen for a proof of concept study 
because there is ample evidence in the literature that the 
NR8383 cell line accumulates amiodarone rather than 
metabolize it, which leads to an increase in size due to the 
accumulation of compound and disruption of lipid 
metabolism22–24. 
Amiodarone is an anti-arrhythmic drug; its mode of action is to 
delay the re-polarization of cardiac smooth muscle cells which 
translates into a steadier heartbeat, however, despite its 
effectiveness, it causes serious side effects and is therefore only 
prescribed to patients as a last resort25. Amiodarone is known to 
accumulate inside macrophages causing phospholipidosis 
(PLD) which under a light microscope gives rise to what appear 
to be  “holes” in the cytoplasmatic region; this is known in 
microscopy as a “foamy” cell24,26,27. However, this phenotypic 
change does not confirm the presence of compound, only drug 
induced morphological changes. It is not known if the 
compound undergoes metabolic degradation whilst in the 
lysosome, or if exocytosis of the compound occurs as the cells 
try to cope with the compound accumulation28. Furthermore, 
amiodarone has a high Log P value (7.64) and therefore has 
good ToF-SIMS sensitivity29 . 
To the best of our knowledge, our previous publication21 was 
the first time unlabelled drug was imaged in a single 
mammalian cell using ToF-SIMS at physiological levels. For 
drug discovery and development, it is important to evaluate the 
applicability to a wider range of compounds and to other cell 
types that are commonly used in drug discovery. Therefore, 
here we investigate the applicability of ToF-SIMS to image 
uptake of amiodarone into Hek293, HeLa and HepG2 cells.  
The Hek293 cell line is commonly used in drug discovery 
research and so is arguably of wider relevance than NR8383. In 
addition, the Hek293 cell morphology does not change much 
compared to the more mobile NR8383, whose role as 
macrophages is phagocytosis30–32.  HeLa cells are the most used 
cell line in research, for example, GSK use HeLa cells in an 
assay developed to measure intracellular compound 
concentration33. HepG2 cells have been extensively used for 
research as they are an acceptable hepatocyte model,  these cells 
are very easy to grow, and display epithelial properties, 
therefore are more manageable than hepatocytes34.  
Hek293 and HeLa were chosen for this study not only because 
they are commonly used in drug discovery, but also because we 
do not expect amiodarone to have a distinct biological effect as 
seen in the NR8383 cell line. For HepG2 there is evidence of 
amiodarone playing a role in phospholipidosis.35 
ToF-SIMS is an ultra-high vacuum technique that makes use of 
two beams: the analysis beam and the sputter beam. Primary 
ions collide with the sample surface and through a process 
known as sputtering, secondary ions from the uppermost 
surface (1-2 nm) are emitted and subsequently analysed in a 
mass spectrometer. ToF-SIMS allows 3D imaging of the 
chemical composition, using, typically, Bi3
+ focused ion beam 
for analysis with an Ar2000
+  sputter beam to erode the sample 
surface without causing sub-surface molecular damage36.  
As the majority of drug targets are intracellular3 several 
promising analytical techniques are being developed to study 
drug uptake and target engagement within cells37. The ability to 
visualize unlabelled compounds inside the cell at physiological 
dosages can offer valuable insight on the compound’s behavior 
both on and off-target. In this study, we show evidence of an 
unlabelled pharmaceutical, amiodarone, inside four different 
types of mammalian cell lines using ToF-SIMS analysis. In 
parallel, Liquid Chromatography – Tandem Mass Spectrometry 
(LC-MS/MS) was used to quantify the cell associated drug 
concentration, resulting in a semi-quantitative imaging 
approach. We have previously shown that ToF-SIMS can 
determine if a compound is inside the cell and outside nuclear 
regions23. However, the ToF-SIMS data  is  not readily 
quantitative, since the secondary ion intensities are prone to 
modification by  matrix effects34,38 Here, we compare the 
amount of cell-associated amiodarone in individual (ToF-
SIMS) with the average population (LC-MS/MS) and  
investigate whether the ToF-SIMS intensity can be calibrated 
using LC-MS/MS,  a well validated quantitative technique, to 
determine the amount of drug in cells20.             
 
 
EXPERIMENTAL METHODS  
                                                                                                                                                        
Sample preparation. HepG2, (ATCC HB-8065, Manassas, 
VA), Hek293 (ATCC CRL-1573, Manassas, VA) and HeLa 
(ATCC CCL-2, Manassas, VA) cell lines were grown in Eagle's 
Minimum Essential Medium with 10% dialyzed fetal bovine 
serum (Gibco, USA) for at least 4 passages. NR8383 (ATCC 
CRL-2192, Manassas, VA) were grown in Ham’s F-12K 
Nutrient Mixture (Gibco, USA) supplemented with 15% 
dialyzed fetal bovine serum (Gibco, USA) also for at least 4 
passages. All cell lines were then cultured in a Nunc Lab-Tek II 
Chamber slide system (ThermoFisher Scientific, USA) at a 
density of 0.5x105 cells per mL, which was measured using a 
Vi-Cell-XR (Beckman Coulter, USA). All cell lines were left to 
settle for 2 hours and extra media was added so the final 
concentrations of amiodarone were: 1.2, 2.4, 4.8 and 9.7 
nmol/mL amiodarone hydrochloride (Sigma-Aldrich, CAS 
19774-82-4, and purity ≥ 98%). The cells were left to incubate 
for either 2 or 72 hours at 37ºC and 5% CO2. They were then 
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washed 3 times with 150 mM ammonium formate (Sigma-
Aldrich, USA) pH 7.4.  
The samples used for ToF-SIMS were freeze dried on the lab-
tek glass substrate using a CoolSink XT 96F plate (BioCision, 
USA) under vacuum in a adVantage wizard 2.0 bench top freeze 
dryer (VirTis, USA) for approximately 1 hour, after this they 
were stored at negative 80ºC until analysis. Having been 
brought to room temperature in a vacuum chamber the slides 
were inserted into the ToF-SIMS V. (ION-TOF, Munster, 
Germany) 
ToF-SIMS. Experiments were conducted using a TOF.SIMS 5 
mass spectrometer (ION-TOF, Munster, Germany) in a dual-
beam setup with an electron gun used for charge compensation. 
The instrument was operated in two modes: (1) High-resolution 
imaging mode using a Bi3
2+ analysis beam at 60 keV, and an 
Ar3000
+ sputtering beam at 10 keV in a non-interlaced mode. The 
primary ion beam was in the “Fast Imaging” mode with an 
approximate spatial resolution of 0.25 m. Pulsed delayed 
extraction of secondary ions was employed for improved mass 
resolving power. The 3D images were collected in positive ion 
mode over a 150 μm × 150 μm surface area and 256 × 256 
pixels. In each analysis phase, the Bi3
2+ ion dose was 5.5 × 1010 
ions/cm2, and an Ar3000
+ dose of 8.99×1013 ions/cm2 was used to 
erode the cells between analysis phases. The cells were fully 
eroded after a total of 50 analysis-sputter cycles for the images 
presented in this publication. (2) Low-resolution 
“Spectrometry” mode was used with a higher primary ion beam 
current to increase the number of cells that could be analysed 
(albeit with poorer but sufficient spatial resolution). A Bi3
+ 
analysis beam set at 30 keV and an Ar3000
+ sputtering beam at 
10 keV were used for a total of 20 scans. The Ar3000
+ ion dose 
in each sputter phase was twice of that above so that the total 
Ar3000
+ ion dose was similar between the two experiments. The 
data analysis was performed in SurfaceLab (ION-TOF, 
Munster, Germany) (version 6.5). The data processing for the 
low-resolution mode experiment was performed by defining 
each individual cell as a region of interest and processing the 
dataset to obtain the total amiodarone molecular ion intensity.  
LC-MS/MS. Cells were grown using T175 flasks (Corning, 
USA) and seeded at 1x105 cells/mL, and grown until the density 
was approximately 4.7x106 and then incubated with 
amiodarone at a concentration of 9.7 nmol/mL for 2 hours. They 
were washed 3 times with ammonium formate pH 7.4 by 
scrapping the cells off the flask with the first wash followed by 
2 washes with centrifugation to avoid losing cells in the 
washing process. They were re-suspended in 10 mL of 
ammonium formate and the cell count was determined using a 
Vi-Cell XR (Beckman Coulter, USA). They were then pelleted 
and re-suspended in the appropriate volume of ProNet cell lysis 
buffer Tris pH7.6 (ESI Source Solution, LLC, Woburn, MA) 
depending on the cell density. Appropriate dilutions of the cell 
lysate were performed so the compound signal fell within the 
linear portion of the calibration curve and reserpine was used as 
an internal standard. The samples were analysed using a 
ABI4000 triple quadrupole (Sciex, Framingham, MA) coupled 
to a Waters UPLC system fitted with a Acquity UPLC BEH C18 
1.7µm 2.1x50mm coupled to a Acquity UPLC BEH C18 
VanGuard cartridge 1.7um 2.1x5mm (Waters, Milford, MA). A 
gradient of 2 to 95% organic (0.1% formic acid in acetonitrile, 
being the aqueous eluent 0.1% formic acid in water) in 5 
minutes, operated at a flow rate of 0.5 mL/min was employed. 
Multiple reaction monitoring (MRM) methods were created for 
reserpine and amiodarone with at least 3 transitions for 
amiodarone. The amiodarone calibration curve was obtained 
using the same amount of cell lysate as the samples to account 
for any ion suppression39,40.  
The assay validation showed very good sensitivity, precision 
and linearity with correlation efficiencies greater than 0.97.  
The amount of compound per cell was calculated by 
normalizing the LC-MS/MS result to the cell count obtained for 
each sample. Each sample was run 8 times and had 3 biological 
and 3 technical replicates, therefore 9 samples were analysed 
for each cell line, in a total of 72 LC-MS/MS runs. On average 
the number of cells analysed per injection was approximately 
5000 cells. The data processing was done using Analyst (Sciex). 
The plots were generated in Statistica 64 (StatSoft). 
Imaging Flow Cytometry. NR8383 cells were grown under 
the same conditions as described above for the LC-MS/MS 
experiment, but incubated with amiodarone for 72 hours. 
Hoescht 33342 (Thermo, USA) and Lysotracker Red DND-99 
(Thermo, USA) were added so the final concentrations were 
4µg/mL for Hoescht and 75µM for Lysotracker red. The cells 
were then incubated for 30 minutes at 37ºC and 5% CO2, 
physically detached from the flask using a cell scrapper, washed 
3 times and re-suspended in PBS (Gibco). They were 
subsequently sorted and analyzed using an ImageStream and 
IDEAS software (Amnis Corporation, USA). 
Confocal fluorescent microscopy. NR8383 cells were grown 
and incubated following the same protocol as for the other 
imaging techniques. NR8383 cells were incubated with 
amiodarone for 72 hours at a concentration of 9.7ug/mL. 
Lysotracker red was added to the culture and incubated for 30 
minutes. The media was removed and FluoroshieldTM with 
DAPI (Sigma-Aldrich, USA) mounting media was added to the 
slide and a cover slip placed on top. The cells were then imaged 
with a Leica SP5 confocal microscope using a 40x 
magnification lens. 
High-throughput fluorescent microscopy. NR8383 cells 
were grown in a 96 well plate (Greiner) at the same relative 
density as previous experiments (T175 flasks and the Lab-Tek 
chamber slides) and incubated with amiodarone for 72 hours at 
a concentration of 9.7 nmol/mL using both Lysotracker red and 
Hoescht at the same concentration used for the flow cytometry 
experiment. They were imaged using an InCell 2000 (GE 
Heathcare, USA) with a 100x objective and 0.9 numerical 
aperture (NA) using fluorescent light; the instrument set up was 
done in accordance with  the literature41.  
At least 50 images were acquired per well and each 
concentration was run in duplicate, before and after freeze-
drying. The live images are not shown as focusing was difficult 
due to the semi-adherence nature of the NR8383 cell line. The 
experiment was therefore performed using a confocal 
microscope. 
Electron Microscopy (EM). HeLa cells were grown as 
described above and pelleted and freeze-dried in the same 
manner as the samples prepared for ToF-SIMS. The samples 
were processed into Agar 100 epoxy resin (Agar Scientific, 
Stansted UK). The standard EM preparation involved manually 
processing the sample by dehydrating with a graded series of 
ethanol followed by immersion into acetone and final epoxy 
resin infiltration. 
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The samples were then embedded and polymerised (at 60oC for 
24 hours) and the resulting blocks were sectioned at 
approximately 80nm; stained with Uranyl Acetate/Lead Citrate. 
These were then examined in a Hitachi H7500 transmission 
electron microscope (TEM), operating at 80 kV and 
representative digital micrographs taken. 
 
RESULTS AND DISCUSSION 
The four cell lines in this study, NR8383, HEK293, HepG2 and 
HeLa, were incubated using the same cell numbers with the 
same amiodarone concentrations for comparison by ToF-SIMS, 
LC-MS/MS and imaging flow cytometry. Using a blue nuclear 
Hoechst fluorescent dye and lysotracker red, the imaging flow 
cytometry images shown in Figure 1 illustrate the effect of 
amiodarone on the NR8383 cell line for doses up to 9.7 
nmol/mL. It was apparent that the number as well as size of 
lysosomes increases with the amiodarone dose, also impacting 
overall cell size. The granularity of the cells or internal 
complexity is also affected by amiodarone dosing as can be seen 
by the side scatter light images in Figure 1. NR8383 cells are 
unable to metabolize amiodarone, which accumulates in the 
lysosomes and inhibits group XV phospholipase A223,28,30. 
The effect of amiodarone on Hek293, HepG2 and HeLa cells is 
less well documented. 
Since ToF-SIMS is a vacuum based technique, the samples 
were freeze dried for analysis; it is important to know the extent 
of cell damage or morphological changes caused during this 
process. We studied this using fluorescence microscopy 
imaging of the NR8383 cell line before and after freeze drying 
as shown in Fig 2. These data indicated that the cell morphology 
was not overly disrupted compared to live cells. In addition to 
the fluorescence microscopy data we also used electron 
microscopy to ensure freeze drying was not causing extensive 
damage of the ultra-structure of the cell. The EM shown in Fig 
3 clearly demonstrates ultra-structure consistent with high 
quality preservation of the freeze-dried cells. 
The electron microscopy results (Fig 3) indicated that around 
95% of the cells looked viable with good ultra-structure 
including mitochondria with visible cristae as well as preserved 
Golgi complex, glycogen and endoplasmatic reticulum. 
Therefore, we can conclude that the freeze-drying process has 
little effect on the morphology of the cells which provides some 
confidence in the sample preparation method for the ToF-SIMS 
chemical imaging.  
In Fig 4, we show 2D representations of the ToF-SIMS data  
that integrate the entire signal in the vertical direction as the 
sample is etched away using the gas cluster ion source (i.e. a 
cumulative plan view) for NR8383, HeLa, HeK293 and HepG2 
cells. For each cell type, the large image to the left is a 
composite colour image with red representing the intensity of 
the ribose fragment (m/z 81), blue representing the intensity of 
the phosphatidylcholine fragment (m/z 184) and green 
representing the amiodarone protonated molecular ion intensity 
(m/z 646). These images are shown separately as a panel of 
small images on the right for clarity. The amiodarone is clearly 
detected for each cell type and the intensity appears higher in 
the HeLa and HepG2 cell lines. This high-resolution imaging 
mode ToF-SIMS data clearly shows compound and cell co-
localization for all the cell lines at incubation concentration of 
9.7 nmol/mLwith 2 hours incubation. The relatively short 
incubation time, helps minimize the range in cell size in the 
NR8383 cell line that results from disruption of the lipid 
metabolism33,42. 
To generate sufficient individual cell measurements (n > 50) to 
compare with the average ensemble cell population 
measurements from LC-MS/MS, we use a low-resolution 
imaging mode to increase throughput since acquisition is faster. 
Figure S1 is the analogue of Fig 4 using this mode. It can be 
seen that  the cells can generally still be resolved. For individual 
cell analysis, we define the perimeter of the cell by manually 
defining a region of interest perimeter on the acquired image 
and to calculate the integrated amiodarone ion intensity for the 
cell. In instances when the cells can’t be resolved they are not 
included, and this occurs for approximately 10% of the cells 
analysed for all cell types. For individual cell analysis, we 
specify the perimeter of the cell by manually defining a region 
of interest perimeter on the acquired image and to calculate the 
integrated amiodarone ion intensity for the cell.  
 In Figure 5a we show a total of 329 individual cell ToF-SIMS 
measurements acquired in this way, of cell associated 
amiodarone for the four cell types (NR8383 n = 62; HeLa n = 
86; Hek 293 n = 57; Hep G2 n = 124). Each data point represents 
a single cell measurement, and reveal considerable cell-to-cell 
variation. In Figure S2, we plot frequency histograms show the 
distribution of drug accumulation. It can be seen that NR8383, 
Hek293 and HepG2 exhibit asymmetric distributions skewed 
with the modal amount significantly lower than the mean. This 
is in contrast to the HeLa cells. The variation between 
individual cells can have many reasons including that these cells 
are not synchronized within their cell cycles.  This was not 
undertaken as the effect of the inhibitors required to achieve 
synchronization are unknown and could confuse the analysis; 
having cells within the culture in different parts of the cell cycle 
makes the model more biologically relevant.  
Quantitative measurement achieved using LC-MS/MS of 
amiodarone concentration per cell from large populations (> 1 
million) are in Fig 5b. The LC-MS/MS shows that both HeLa 
and Hek293 cells have lower amiodarone uptake than the 
HepG2 and NR8383 cells. These cells are known to express less 
of the common ABC (ATP-Binding Cassette) and SLC (solute 
carrier) transporters30,43 and this might contribute to the lower 
amount of cell associated compound44,45. Detailed proteomics 
studies such as the one undertaken by Geiger, et al46 could be 
used to provide details on the differences in transporters 
between the different cell lines, but are beyond the scope of this 
study. 
The higher drug uptake for the NR8383 cells can be explained 
by their biological function, as macrophages possess 
remarkable endocytosis capabilities47. Being an immune system 
cell they target microorganisms and other potential threats to 
the host. In this particular case, the threat is the compound and 
as a phagocyte they will try to internalize the compound to 
minimize the damage the drug could cause to other cells, with 
the intent to metabolize it or contain it within45,47. Since they 
cannot metabolize amiodarone, the internal drug concentration 
increases. Amiodarone disrupts the lipid metabolism in 
macrophages causing them to become enlarged with lipid and 
compound laden vesicles. The high amount of drug uptake in 
HepG2 cells is not surprising as amiodarone also causes 
phospholipidosis in these cells35.   
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Most intracellular drug determination studies only report ratios 
of bound versus unbound compound21,34 so it is hard to draw a 
direct comparison between the intracellular drug concentration 
values obtained here and other studies. However, previous 
publications report intracellular drug concentration of the same 
order of magnitude as those presented in Fig 5b48  measured by 
LC-MS/MS. Furthermore, the intracellular concentration also 
increases in the same order as the referenced study21,34,48 which 
is approximately 10 to 50 times higher than the extracellular 
media concentration49.   
As one of the objectives of this paper was to determine if there 
was any correlation between the individual cell measurements 
by ToF-SIMS and the average cell population measurements 
with quantified LC-MS/MS, we compare these two data sources 
in Fig 6. The ToF-SIMS individual cell measurements for HeLa 
show a much higher intensity than would be expected based on 
the relationship of the other three cell types. Repeat 
measurements of the samples with the high-resolution imaging 
mode (Figure S3) are consistent with Figure 6, which indicates 
that the ToF-SIMS measurements are reproducible (between 
different days and different analysis modes). We do not have an 
explanation for why the HeLa data is inconsistent with the 
monotonic relationship between ToF-SIMS and LC-MS/MS for 
the other cells, and consequently we cannot in this study state 
with confidence that there is an overall correlation between 
amiodarone uptake in individual cell ToF-SIMS measurements 
and ensemble population LC-MS/MS measurements. The 
significant variability associated with the ToF-SIMS 
measurement is far greater than the reproducibility of the 
technique despite the relatively high number of cells analyzed 
indicating significant cell to cell drug uptake differences. 
 Elsewhere50, we demonstrate that the SIMS protonated 
amiodarone molecular ion intensity is approximately linearly 
proportional to the amiodarone incubation concentration for 
NR8383 cells. The phenomena observed for HeLa cells, could 
be explained by the biological effect of amiodarone in HeLa 
cells at the concentration used for the study, which is relatively 
high and signs of cytotoxity are beginning to be observed. This 
could be addressed in the future using ToF-SIMS or using an 
orthogonal technique such as electron microscopy to investigate 
changes in lipid structures within HeLa cells with increasing 
levels of amiodarone. 
 
 
CONCLUSION 
We have shown that ToF-SIMS is able to identify and localize 
the drug amiodarone at therapeutic dosing concentrations (up to 
9.7 nmol / mL) in four different cell types, NR8383, HeLa, 
Hek293 and HepG2. A freeze-drying sample preparation 
method is used and a study with confocal microscopy 
incorporating nuclear and lysosome stains suggests that there is 
no significant disruption of the cell structure for the NR8383 
cells (Figure 2). Equally, electron Microscopy of freeze dried 
HeLa suggests that the internal structural integrity of these cells 
is intact supporting the relevance of the ToF-SIMS of this cells 
prepared in this manner (Figure 3).  
We show by ToF-SIMS that there is considerable variation in 
drug uptake at the individual cell level of the same type. 
Analysis of the frequency histograms of the amiodarone signal 
intensities reveals an asymmetric distribution for NR8383, 
HepG2 and Hek293 cells and a distribution closer to a normal 
distribution for HeLa cells (Figure S1). Quantitative 
measurements of the amount of cell associated amiodarone for 
the population average shows that NR8383 and HepG2 cells 
have the largest amount of amiodarone with on average 2.38 
and 2.60 pg per cell, respectively and HeLa and Hek293 have a 
significantly less amiodarone with 0.43 and 0.36pg per cell, 
respectively. For HeLa cells there is significant discrepancy 
between the single cell ToF-SIMS measurements compared 
with the LC-MS/MS measurement. For the other cells, a 
monotonic correlation could exist but the high scatter in the 
single cell data makes this difficult to state with confidence. 
Especially since we have no reasonable explanation to exclude 
the HeLa data. 
We report a method using ToF-SIMS imaging that has good 
potential for studying the behavior of single cells and in the 
future to also look at drug efficacy and metabolism. This could 
open the possibility for further investigations of what causes 
cells to have such varied amounts of drug uptake. Challenges 
remain in the quantification of drug uptake. 
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Figure 1: Imaging flow cytometry images of NR8383 cell line when incubated with different concentrations of amiodarone after 72 hours. 
The cells have been fluorescently stained with the nuclear dye Hoescht 33342 (blue) and Lysotracker (red), which stains the lysosome. The 
number and size of lysosomes increases with the treatment concentration (white line scale bar is equal to 10µm). 
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Figure 2: (A) Confocal fluorescence microcopy of live NR8383 cells incubated for 72 hours with 4.84 nmol/mL amiodarone exposure and 
staining as the live cells using a x40 objective on a Leica SP5 system with DAPI as a nuclear stain and Lysotracker red to stain the lysosome.  
(B) Image of high throughput fluorescent microcopy of freeze dried NR8383 cells undergoing the same amiodarone exposure and staining 
as the live cells using an Incell 2000 and a x100 objective. Both these experiments show NR8383 cells incubated for 72 hours in A the 
concentration is 4.84nmol/mL amiodarone (as at 9.7nmol/mL the vast majority of the cells were not adherent and therefore difficult to image) 
and in B is 9.7nmol/mL amiodarone. In both A and B the highest possible spatial resolution images were acquired given the difference in 
cell state. 
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Figure 3: Electron microscopy images of freeze-dried HeLa cells. (A) HeLa cells section at direct magnification of 12000x. (B) HeLa cell 
mitochondria at 25000x direct magnification. RER stands for Rough endoplasmatic reticulum and M stands for mitochondria. 
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Figure 4 : ToF SIMS 2D images of a 3D data acquired from cells completely consumed by the argon cluster source during analysis. There 
were acquired in the higher spatial resolution mode, (A) NR8383 cells, (B) HeLa cells, (C) Hek 293 cells, (D) HepG2 cells, they were 
incubated for 2 hours with 9.7 nmol/mL. Composite image where Red represents Ribose m/z 81 [M+H] +, blue shows the signal from the 
phosphatidylcholine lipid fragment (m/z 184) ), and green shows the amiodarone signal (m/z 646 
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Figure 5: 5(A) box plot showing single cell population measurements for each cell type using the ToF-SIMS integrated amiodarone 
protonated molecular ion counts for each cell NR8383 n = 62; HeLa n = 86; Hek 293 n = 57; HepG2 n = 124 (B) box plot showing cell 
population measurement using the LC-MS/MS assay, for each sample approximately 4.7x106 cells were used.  
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Figure 6: Comparison of the average cell associated amiodarone intensity determined by ToF-SIMS from a number of individual cells with 
the amiodarone cell uptake determine by LC-MS/MS from ensemble measurement of a large cell population (approximately 5000 per 
injection) for all cell lines incubated with 9.7nmol/mL for 2 hours. The diamond represents the NR8383 cell line, the square represents HeLa 
cells, the circle represents HepG2 and the triangle represents Hek293 cells. The error bars represent one standard deviation from the average 
value.  
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